Problems at Lupin’s plant in Goa, India, hit the drugmaker’s latest earnings with a double whammy, undercutting its U.S. sales while raising costs.

GSK's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead.

India’s Granules bought a U.S. R&D facility in 2014 and is now ready to add manufacturing as part of plans to expand significantly in the U.S. market.…

The manufacturing problems at Sun Pharma’s key Halol, India, plant have again stymied approval of a new drug from Sun's novel drug development group,…

China's FDA proposed several drug policy changes, Indian drugmakers cashed out on generics and BI opened a Shanghai plant.

Germany’s Boehringer Ingelheim has opened a €70 million biologics plant in Shanghai to do contract manufacturing targeted at China's growing appetite for…

India’s Dr. Reddy’s Laboratories, which has been whiplashed repeatedly by FDA actions against its plants, saw its sales in the U.S. fall markedly in the last…

​​​​​​​Rocked by a corruption scandal in Korea, Novartis is working to strengthen and simplify its global ethics and compliance approach.

The CFDA aims to speed orphan meds to market with conditional OKs for drugs approved abroad, even without any in-China trial data.

Pharma Asia